Sorry, you need to enable JavaScript to visit this website.
  • Branded drugs are more expensive because they’re newer, generally groundbreaking, and often for conditions that are difficult to treat. However, after a certain period of time, these same innovative medicines become generic medicines.

  • The difference between our approach and that of many other companies is that when a medicine becomes a generic, we still assume responsibility. Rather than focus on just what’s in development, we continue to closely monitor the quality, safety, and reliability of our generic medicines.

Science & Innovation

In Search of a New Hemophilia Treatment

Despite significant advancements in hemophilia treatments over the past several decades, balancing management of the disorder while maintaining regular day-to-day activities remains a challenge.
Still from hemophilia video 2 thumbnail
Science & Innovation

Viral vs Bacterial Infections: Different Pathogens, Different Approaches

Learn about the key differences between viral and bacterial infections and the innovative prevention and treatment options being worked on for each type.
Woman sneezing into tissue thumbnail
Science & Innovation

Pharma Peers Unite to Build DNA-Encoded Libraries

Scientists build a library of millions or billions of compounds, each tagged with a unique DNA “barcode.” They are tasked with exploring DNA-encoded libraries technology, DELs, to help accelerate the earliest stages of drug discovery.
Pfizer scientists stacking books cartoon art thumbnail

The medicines available today have taken an average of 12 years to develop. With dedication, creativity, and science, we can significantly cut that time.

  • 00Phase 1
  • 00Phase 2
  • 00Phase 3
  • 00Registration
  • 00Total

Learn more about the process of joining a clinical trial and find a trial near you.

Go to Pfizer Clinical Trials Site Details